Research Study

A Randomized, Open-label, Phase 3 Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing
Principal Investigator 
Kevin Song

Overview

Body Locations and Systems 
Blood
Disorders and Conditions 
Multiple Myeloma
ClinicalTrials.gov# 
NCT02412878
Status 
Closed to Recruitment
Study Start/End 
Sep 25, 2015 to Sep 1, 2018
Locations 
Vancouver General Hospital
Name/Title 
Sarah MacEwan, Research Assistant
Phone 
604-875-4863
Purpose of Study 

The purpose of the study is to compare once-weekly carfilzomib dosing in combination with dexamethasone to twice-weekly carfilzomib dosing in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma, previously treated with bortezomib and an immunomodulatory agent (IMiD).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.